# Wall Street’s Wildest Showdowns: Bulls vs. Bears!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-09-30T23:28:24.242Z
Source: https://newsyai.com/edition/64a568e4-d2b0-4af0-bfe0-eeb59bdfc717
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

**Wall Street's Most Polarizing Shitshows: 3 Stocks Where Bulls and Bears Are Throwing Hands (and Maybe Some Feces) — Fresh Edition, September 30, 2026**

Ah, September 30, 2026. Futures are mixed, the Dow's flat-ish, Nasdaq's riding that AI wave like it's the only game in town, and crude's doing its volatile dance. Forget the last edition's LNG export drama, Bitcoin miner pivots, and defense roll-ups—these three tickers have the Street more divided than a family group chat after Thanksgiving politics. Sky-high short interest, turnaround tales, AI voice bets, and AI-drug moonshots. I've scoured the latest short data, news, and chatter for *fresh* developments. Bulls smell glory; bears smell Chapter 11 or dilution hell. Then I drop the first-principles beatdown.

### 1. Hertz Global Holdings (HTZ) – Rental Car Comeback King or Debt-Laden Lemon?
HTZ carries eye-watering short interest north of 60% of the float (some screens peg it even higher amid heavy trading volume), with the stock languishing around $1.60–$1.70 and a market cap under $1B.[[1]](https://www.findmymoat.com/short-interest)[[2]](https://www.marketbeat.com/articles/2-short-squeeze-candidates-waiting-for-the-right-catalyst/)

**Bull Case (The "Fleet Economics Reboot" Crew)**  
- Management's pivoting hard from volume-chasing to yield maximization—recent quarters show RPD (revenue per day) and RPU (revenue per unit) growth despite a smaller fleet. The U.S. core fleet is now mostly shiny new Model Year 2025/2026 rides, which should slash maintenance costs and boost residuals.  
- Targeting ride-share/delivery drivers extends vehicle lifecycles and monetization. Analysts see a path back to profitability if used-car values stabilize and operating costs get reined in. High shorts + any positive catalyst (earnings beat, debt extension news) could spark a violent squeeze in this low-float name.[[2]](https://www.marketbeat.com/articles/2-short-squeeze-candidates-waiting-for-the-right-catalyst/)[[3]](https://finsee.ai/earnings/htz/2026/q2/en/)

**Bear Case (The "Value Trap with Wheels Falling Off" Skeptics)**  
- Massive debt load, ongoing losses (hundreds of millions), and a history of bankruptcy drama make it a leveraged bet on used-car prices and consumer spending. Operating costs are missing targets, quality of earnings looks sketchy with one-time gains propping things up, and analysts are mostly Hold/Sell with targets clustered low.  
- EV fleet experiments flopped before; high leverage (net debt/EBITDA in the stratosphere) and insider selling add to the "falling knife" vibes. Shorts are crowded for a reason—any macro slowdown or residual value crash and this thing craters.[[4]](https://trendmatrix.com/stocks/HTZ)[[5]](https://finance.yahoo.com/markets/stocks/articles/3-reasons-avoid-htz-1-200305073.html)

**My First-Principles Take**: Cars want to be driven and depreciated predictably—physics and economics favor efficient fleet utilization over endless expansion. HTZ has the brand and scale, but unit economics only work if depreciation, maintenance, and used-car cycles cooperate without endless debt service. It's a classic cyclical recovery bet with leverage dialed to 11. At these short levels, it's pure volatility fuel: nail the pivot and shorts get torched; stumble on costs or residuals and it gets ugly fast. High-conviction either way—size small, you beautiful degenerates.

### 2. SoundHound AI (SOUN) – Voice AI Wizard or Dilution-Fueled Acquisition Disaster?
SOUN sports short interest around 40% of the float (up recently, with days-to-cover near 7), amid a market cap in the low billions and heavy trading.[[1]](https://www.findmymoat.com/short-interest)[[6]](https://curvedtrading.com/stocks/soun/short-interest/)

**Bull Case (The "Conversational AI Empire Builder" Optimists)**  
- Rapid revenue growth in voice AI for autos, restaurants, and more, with OASYS platform momentum and a big LivePerson acquisition adding scale, customers, and cross-sell potential. AI hype + execution on integrations could drive explosive adoption as voice interfaces explode.  
- Shorts are overcrowded; positive catalysts on deals, revenue beats, or AI tailwinds could trigger a squeeze. Analysts see upside in the high-growth software story if the acquisition pays off without killing margins.[[7]](https://www.fool.com/investing/2026/09/03/with-nearly-40-short-interest-is-soundhound-stock/)

**Bear Case (The "LivePerson Debt Bomb + Cash Burn" Doubters)**  
- The LivePerson deal brings troubled assets, debt, and integration risks in a declining business. Heavy reliance on future raises for debt retirement risks dilution in a pre-profit name trading at rich multiples. Cash burn persists, and competition in AI voice is brutal.  
- Short interest reflects skepticism on sustainable profitability and whether hype translates before the music stops. Recent financing vibes and insider sales add fuel to the bear fire.[[7]](https://www.fool.com/investing/2026/09/03/with-nearly-40-short-interest-is-soundhound-stock/)

**My First-Principles Take**: Voice wants seamless, contextual intelligence—physics and user behavior favor AI that actually understands intent over gimmicks. SOUN has the tech and vertical traction, but per-share economics only compound if acquisitions deliver synergies without drowning in debt or dilution. It's a high-stakes software bet on AI adoption cycles. At current shorts, it's momentum rocket fuel: deliver on integrations and win big; fumble execution or need constant capital and shorts feast. Probability of survival: solid if AI keeps printing; outsized riches: flawless timing required.

### 3. Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Unicorn or Clinical Cash Incinerator?
RXRX boasts short interest around 35% of the float, with a ~$2B market cap, massive losses, and clinical-stage pipeline in a hot-but-risky AI-biotech niche.[[1]](https://www.findmymoat.com/short-interest)[[8]](https://businessquant.com/stocks/rxrx/)

**Bull Case (The "Platform-to-Pipeline Payoff" Gang)**  
- AI-native discovery platform generating real partnerships (Roche, etc.), milestone revenue, and a fortress balance sheet into 2028 with disciplined burn reduction. Lead assets like REC-4881 in FAP show promising Phase II polyp reduction and durability signals; multiple readouts ahead could de-risk the thesis.  
- Analysts see big upside (targets implying 70%+ gains) if the platform delivers first-in-class drugs in rare diseases. Shorts are crowded—positive clinical or partnership news could spark a squeeze.[[8]](https://businessquant.com/stocks/rxrx/)[[9]](https://stockanalysis.com/stocks/rxrx/)

**Bear Case (The "Burn Rate Nightmare + Unproven AI" Crew)**  
- Relentless cash burn (hundreds of millions annually), no approved drugs, and clinical/execution risks in a field where most AI-drug bets flame out. Platform hype hasn't fully translated to hard endpoints or commercial wins yet; dilution overhang looms if milestones slip.  
- Shorts highlight the gap between narrative and reality—NVIDIA exit vibes and accelerating losses make it a value trap until tangible approvals or big pharma validation hits.[[8]](https://businessquant.com/stocks/rxrx/)

**My First-Principles Take**: Drug discovery wants scalable, data-driven iteration—biology and computation favor AI that maps vast chemical spaces faster than traditional labs. RXRX has the industrialized platform and capital runway, but per-share economics only work if clinical translation delivers without endless burn or dilution. It's a classic platform bet: nail synergies between AI insights and real-world trials for glory; fumble readouts and it becomes a slow grind. At these short levels, pure binary-event volatility—strong catalysts win; missteps crush. High-risk, high-reward for the bold.

There you have it—three fresh brawls proving disagreement is the market's favorite drug. Do your own damn homework, size like an adult, and remember: the tape stays irrational longer than your margin account can breathe. Sources pulled from latest short data, news, and analysis as of late September 2026. Trade responsibly, you magnificent animals.
